熱門資訊> 正文
Viking Therapeutics每股收益未达标导致股价下跌7%
2025-07-24 05:51
- Viking Therapeutics (NASDAQ:VKTX) is down ~7% in after-hours trading Wednesday after its Q2 bottom line results missed the mark. The company did not report any revenue.
- The biotech saw its net loss widen to ($0.58) from ($0.20) in the year-ago period.
- Viking was hurt in the quarter by a ~119% increase in total operating costs to ~$74.6M.
- The company ended the quarter (June 30) with cash and cash equivalents of ~$33.9M compared to ~$26.7M on Dec. 31, 2024.
More on Viking Therapeutics
- Viking Therapeutics: What's Next After GLP-1 Hype Dies Down And Competition Intensifies
- Viking: I'm Bullish On Oral/Injectable GLP-1 Obesity Data Catalysts
- Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential
- Viking Therapeutics GAAP EPS of -$0.58 misses by $0.12
- Madrigal, Viking among notable gainers after Altimmune’s MASH setback
推薦文章
一周財經日曆 |下周重磅事件搶先看：美聯儲利率決議、科技巨頭財報密集來襲
美股機會日報 | 9月CPI低於預期！三大股指期貨直線拉昇；英特爾盤前大漲超5%
一周IPO | 八馬茶業、滴普科技預計下周二上市；傳賽力斯最快下周一招股
華盛早報 | 中美將於今起進行經貿磋商；盤后漲超7%！英特爾Q3營收增長2.8%
營收創新高、利潤暴跌29%！馬斯克的AI豪賭能撐起特斯拉的未來嗎？
財報前瞻 | iPhone17熱銷「帶飛」蘋果股價！大行績前集體齊聲看漲，Q4季報重點關注什麼？
甲骨文兩日跌超10%，「超預期宏偉目標」不再「吃香」？
小馬智行、文遠知行回港上市，迎Robotaxi 的deepseek時刻？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
